
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2010

ONCOGENEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction of Incorporation)	033-80623 (Commission File Number)	95-4343413 (IRS Employer Identification No.)
1522 217th Place S.E. Bothell, Washington (Address of Principal Executive Offices)		98021 (Zip Code)

Registrant's telephone number, including area code: **(425) 686-1500**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On March 4, 2010, the Board of Directors of OncoGenex Pharmaceuticals, Inc. approved new charters for the Compensation Committee and the Nominating and Governance Committee, to supersede in their entirety the Company's prior charters for these two committees. The new charters were adopted as part of an annual review of the Company's various corporate governance policies. Copies of the new charters are available on the Company's website at www.oncogenex.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ONCOGENEX PHARMACEUTICALS, INC.
(Registrant)

Date: March 10, 2010

By: /s/ Cameron Lawrence
Name: Cameron Lawrence
Title: Principal Financial Officer